Zevra Therapeutics (ZVRA) Non-Current Debt (2014 - 2025)

Zevra Therapeutics has reported Non-Current Debt for 8 years, with the latest figure at $61.9 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Debt rose 4.07% year-over-year to $61.9 million; the trailing twelve-month figure through Dec 2025 stood at $61.9 million (up 4.07% YoY), and the FY2025 full-year result was $61.9 million, up 4.07% from the prior year.
• Non-Current Debt for Q4 2025 stood at $61.9 million, up from $61.3 million in the prior quarter.
• The five-year high for Non-Current Debt was $61.9 million in Q4 2025, with the low at $98000.0 in Q1 2021.
• Historically, Non-Current Debt has averaged $40.1 million across 5 years, with a median of $58.6 million in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Debt slumped 60.37% — and 2024, when it surged 1074.58%.
• Zevra Therapeutics' Non-Current Debt stood at $98000.0 in 2021, then surged by 12961.22% to $12.8 million in 2022, then slumped by 60.42% to $5.1 million in 2023, then surged by 1074.58% to $59.5 million in 2024, then increased by 4.07% to $61.9 million in 2025.
• The last three Non-Current Debt figures came in at $61.9 million (Q4 2025), $61.3 million (Q3 2025), and $60.7 million (Q2 2025), per Business Quant data.